ISRCTN10844309 2019.

Methods	Study design: cluster RCT Duration: 69 weeks Location: community pharmacies in 3 locations of Portugal (Faro, Lisboa and Setubal)
Participants	Population: adults with asthma or COPD Baseline characteristics: NR Inclusion criteria: aged ≥ 18 years; self‐reported asthma or COPD; using Breezhaler, Ellipta, Spiromax, Turbohaler, pMDI or Respimat Exclusion criteria: NR
Interventions	Treatment arms Pharmacist‐lad educational programme to improve inhaler technique Usual care provided by pharmacies
Outcomes	Proportion of people with asthma or COPD achieving 100% in assessment of inhaler technique, inhaler technique score, quality of life (CAT), ACT (for asthma) and mMRC (for COPD), adverse drug events; disease‐related exacerbations, healthcare utilisation and cost
Notes	Funding: Associação Nacional das Farmácias (ANF, Portuguese National Association of Pharmacies) Identifier: ISRCTN10844309